Clévio Nóbrega (CN) has a PhD in Molecular Biology and Cytogenetics from a joint project between the University of Barcelona (ES) and the University of Madeira (PT). In 2007, he joined the Center for Neuroscience and Cell Biology, first as postdoctoral fellow and then as an invited assistant researcher. In 2016, he joined the University of Algarve (UAlg) as an assistant professor and obtained in 2022 the Habilitation title in Biomedical Sciences. Since 2021, CN is the President of the Pedagogic Council of the School of Medicine and Biomedical Sciences and currently Associate Professor. At UAlg he created the research group in Molecular Neuroscience and Gene Therapy as Principal Investigator, coordinating several funded research projects to up to 3 million euros. Currently, the group has 8 PhD holders, 10 PhD and 3 Master students, and 4 technicians. So far, CN (co)supervise(d) 7 postdoctoral fellows, 13 PhD and 33 Master students, and >65 undergraduate students. He published 60 papers in peer-reviewed journals, including Brain, Acta Neuropathologica, PNAS, Cell Death & Dis., among others. He is the author of 4 patents, 3 granted and 1 provisional, and the co-founder of the biotech startup AQuracy Therapeutics. He published 3 books, 2 as editor and one as author. CN received several awards and distinctions, including the Young Scientist Lectureship Award in 2017 by the European Society for Neurochemistry (ESN). CN established the Algarve Biomedical Center Research Institute (ABC-Ri), serving as its director since April 2021. Currently, he is also the Vice President of the academic center (Algarve Biomedical Center—ABC) and the President of the Executive Board of the ABC Collaborative Laboratory. Since 2019, he has been a member of the executive board of the Portuguese Neuroscience Society, and from 2023, is a member of the ESN council. CN regularly acts as a peer reviewer for indexed journals and for national and European funding bodies, including the European Commission, among others.